Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor.

Authors: Jacobson, Eric M; Hugo, Eric R; Tuttle, Traci R; Papoian, Ruben; Ben-Jonathan, Nira

Published In Trends Endocrinol Metab, (2010 Nov)

Abstract: Breast and prostate cancers are hormone-sensitive malignancies that afflict millions of women and men. Although prolactin (PRL) is known as a survival factor that supports tumor growth and confers chemoresistance in both cancers, its precise role in these tumors has not been studied extensively. Growth hormone and placental lactogen also bind PRL receptor (PRLR) and mimic some of the actions of PRL. Blockade of the PRLR represents a novel treatment for patients with advanced breast or prostate cancer with limited therapeutic options. This review discusses different approaches for generating PRLR antagonists. Emphasis is placed on technological advances which enable high-throughput screening for small molecule inhibitors of PRLR signaling that could serve as oral medications.

PubMed ID: 20846877 Exiting the NIEHS site

MeSH Terms: Animals; Breast Neoplasms/genetics; Breast Neoplasms/metabolism; Breast Neoplasms/therapy*; Carcinoma/therapy*; Female; High-Throughput Screening Assays/methods; Hormone Antagonists/isolation & purification; Hormone Antagonists/therapeutic use; Humans; Male; Models, Biological; Models, Molecular; Molecular Targeted Therapy/methods*; Prostatic Neoplasms/genetics; Prostatic Neoplasms/metabolism; Prostatic Neoplasms/therapy*; Receptors, Prolactin/antagonists & inhibitors*; Receptors, Prolactin/chemistry; Receptors, Prolactin/metabolism; Receptors, Prolactin/physiology; Therapies, Investigational/methods

Back
to Top